LATEST NEWS
PetVivo.ai Breaks the Mold: Launches Video Explainer Because "Nobody Reads Tech Press Releases Anymore"
What does PetVivo Do?
PetVivo (OSTQX: PETV) is a veterinary biotech and medical device company focused on adapting human medical technologies for the veterinary market. Their products help improve the health, mobility, and quality of life of companion animals, including dogs and horses, by addressing conditions such as arthritis and other joint-related ailments. PetVivo combines innovative research with practical solutions to bring advanced therapies to animals in need.
5 Key Reasons PetVivo Represents a Compelling Opportunity in Veterinary Health Innovation
IDENTIFYING THE OPPORTUNITY
PETV is positioned in a developing area of potential
We are in a developing blast zone and are seeing early sparks.
TARGETS
Key Level #1: $1.37 (+23.54%)
Key Level #2: $1.50 (+35.04%)
Key Level #3: $1.68 (+51.36%)
Potential Support: ~$0.83
PetVivo Holdings, Inc. (OTCQX: PETV)
As advancements in veterinary biotechnology and medical devices continue to transform animal healthcare, companion animals are at the center of this innovation. PetVivo’s technologies provide the foundational solutions that address arthritis and other joint-related conditions in dogs, horses, and other pets, improving mobility, comfort, and overall quality of life.
As demand for advanced veterinary treatments grows—driven by rising pet ownership, increasing insurance coverage, and a focus on higher-quality care—opportunities within this sector are expanding rapidly. To fully capitalize on the growth in veterinary health innovation, it is essential to have exposure to companies leading the development and commercialization of these breakthrough therapies.
PetVivo Holdings, Inc. (OTCQX: PETV) offers investors a focused investment in the veterinary biotech and medical device space, targeting the companies pioneering solutions that improve animal health and wellbeing
Revolutionizing Mobility: Untreated vs. Spryng®-Treated Joints
PetVivo is strategically positioned to capitalize on the expanding animal health market. Its therapies, including Spryng with OsteoCushion Technology, are designed for scalable use in veterinary clinics, improving mobility, comfort, and overall quality of life for pets.
PetVivo’s new facility is positioned to scale, with the capacity to produce up to 500,000 units annually, representing potential revenue of up to $100 million. The company also maintains a robust pipeline of 17 products at various stages of development and commercialization. By focusing on veterinary medical devices that do not require FDA premarket approval, PetVivo can accelerate time-to-market, bringing innovative solutions to veterinarians and pets faster than traditional pharmaceutical pathways. This combination of scalable production and a strong pipeline positions the company to meet growing demand while exploring future opportunities in the veterinary and broader biomedical markets.
Meet The PetVivo Holdings, Inc. Management Team
John Lai
CEO, President & Director
Mr. Lai has been a director and senior executive officer since March 2014, serving in various capacities that include Principal Financial Officer, President and CEO; and serving as our Chief Executive Officer from March 2014 to May 2017 and June 2019 to present. From March 2012 to April 2016, Mr. Lai also was Chief Executive Officer and a director of Blue Earth Resources, Inc., a small public company which acquired and managed working interests in producing oil and gas leases in Louisiana. Mr. Lai has over thirty years of senior executive and operational management and financial experience while holding key executive positions with several public companies in various industries.
In 1992 Mr. Lai founded and until December 2012 was the principal owner and President of Genesis Capital Group, Inc., which provided significant consulting services to many public and private companies in the powersports, technology and other industries, while advising its clients in corporate development, mergers and acquisitions, and private and public capital-raising through equity offerings. Mr. Lai’s role as a co-founder of the company and his many years of experience as a chief executive officer of many public or private companies are material factors regarding his qualifications to serve on our Board of Directors.
Garry Lowenthal
Chief Financial Officer
Mr. Lowenthal has served as Chief Financial Officer of PetVivo since March 2024 and brings more than 25 years of experience in senior financial, operational, and corporate leadership roles across both private and public companies. His background includes extensive expertise in equity capital raising, overseeing private placements and public offerings, as well as broad financial and corporate management experience. He has served as Managing Partner of Security First International, Inc., a CFO advisory and management consulting firm, and previously held roles as Director, Executive Vice President, and CFO of Fision Corporation (OTCQB: FSSN).
In addition to his operating CFO experience, Mr. Lowenthal has deep knowledge of corporate governance and fiduciary responsibilities, supported by his service on the national board of Financial Executives International (FEI), including roles as President of the Twin Cities Chapter and Chairman of FEI’s national technology committee. He holds a Master’s degree in Taxation and Finance and a Bachelor’s degree in Accounting from the University of Minnesota and has served on the Alumni Advisory Board of the Carlson School of Management. His earlier career at PricewaterhouseCoopers (PwC) and Deloitte, combined with long-standing community leadership roles, provides him with a well-rounded perspective as both a financial executive and trusted advisor to boards of public companies.
John Dolan
Chief Business Development Officer & General Counsel
Mr. Dolan has been working with the Company as a director and/or an officer since March 2014. He has served as our Chief Financial Officer from March 2014 to November 2017, General Counsel since October 2019 and Chief Business Development Officer since August 2021. Mr. Dolan also has served as a director for a number of early stage companies, such as TERRACOH, Inc. and Traust Structured, LLC. Mr. Dolan was also a shareholder in the intellectual property group of the Minneapolis law firm of Fredrikson & Byron, where he specialized in securing and protecting domestic and foreign patent and other IP rights, as well as providing counsel to various clients involving mergers and acquisitions, private equity and other related corporate matters.
During the past five years, Mr. Dolan has also provided consulting services to several early stage companies on all aspects of IP asset protection as well as new technology and corporate development. His extensive career in intellectual property development and corporate counsel includes serving as a patent examiner with the U.S. Patent and Trademark Office (USPTO).
Josh Wilhelm
Vice President of R&D and Clinical Trials
Mr. Wilhelm was the Director of Islet Manufacturing and R&D at the Schulze Diabetes Institute (“SDI”), coordinating the islet isolation and research activities of the "Isolation Core". As the Director of Manufacturing at SDI, Mr. Wilhelm supervised all cGMP manufacturing, process engineering, and quality systems. He further assumed the role at SDI of lead supervisor for human clinical islet manufacturing, managed both clinical and pre-clinical activities of the team and pursued research related to understanding and improving islet isolation yields and islet graft function. Mr. Wilhelm obtained his M.S. in Biomedical Engineering from the University of Minnesota in 2004 and entered industry to explore the real-world application of biomaterials and cell, tissue, and gene therapies for Medtronic, Inc and several local medical device and biotechnology start-ups.
April Boyce
Vice President of Sales & Marketing
Ms. Boyce has over 25 years of leadership experience in consumer-packaged goods (CPG), international marketing, sales, strategic partnerships, and licensing. Before transitioning to the mid-market and start-up sectors, she held significant positions at Procter & Gamble (P&G) and Clorox. In the mid-market, Ms. Boyce led global marketing for the global housewares company Interdesign, Inc., where she served as Vice President of Global Marketing and Branding. Most recently, she served as Chief Commercial Officer for the animal health pet-tech company, Link. Ms. Boyce holds a BS in Advertising from the University of Florida.
Bryan Monninger
Vice President of Distributor Relations & Corporate Accounts
Mr. Monninger has over 20+ years within the animal industry, focused in the areas of Sales and Marketing with growing levels of responsibility. Experiences include Hill’s Pet Nutrition Science Diet and Prescription Diet brands, Novus International for large animal feed additives, and Lintbells/YuMOVE in the companion animal joint supplement category. This range of roles has allowed for managing large existing businesses, bringing significant scientific innovation to the profession, as well as building a veterinary business from zero. Bryan has successfully built and developed both veterinary sales and marketing teams delivering market share, revenue, and profit growth to multiple businesses. Bryan has a strong passion for the veterinary profession and the animal industry in its special mission to further the human/animal bond.
Sources
- https://www.petvivo.com/
- https://finance.yahoo.com/quote/PETV/
- https://www.petvivoanimalhealth.com/
- https://www.petvivo.com/team-bios/
Disclaimer
Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.
By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.
This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.
Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.
The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.
Compensation: Pursuant to an agreement between The Investing Authority and PetVivo Holdings, Inc. to disseminate information about OTCQX: PETV from 2025-12-19 to 2026-1-16. The Investing Authority has been paid $30,000 USD. The Investing Authority has hired Virtus Media Group LLC to publicly disseminate information about OTCQX: PETV via digital communications. Virtus Media Group has been paid $14,500 USD.
